tiprankstipranks
9 Meters Biopharma (NMTRQ)
OTHER OTC:NMTRQ
US Market
Holding NMTRQ?
Track your performance easily

9 Meters Biopharma (NMTRQ) Income Statement

1,977 Followers

9 Meters Biopharma Income Statement

Last quarter (Q1 2023), 9 Meters Biopharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, 9 Meters Biopharma's net income was $-13.87M. See 9 Meters Biopharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
------
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 43.44M$ 42.02M$ 36.76M$ 60.88M$ 25.58M$ -18.22M
Operating Income
$ -43.44M$ -42.02M$ -36.76M$ -60.88M$ -25.58M$ -18.22M
Net Non Operating Interest Income Expense
$ -2.77M$ -2.17M$ -24.48K$ -4.03M$ -1.64M$ -5.99M
Other Income Expense
$ 76.24K$ -416.70K$ -7.00K$ -3.37M$ -93.83K$ -50.00K
Pretax Income
$ -46.28M$ -43.77M$ -36.78M$ -61.50M$ -27.13M$ -24.16M
Tax Provision
$ -41.00K$ -41.00K$ -27.90K$ -661.30K$ -41.30K$ -603.90K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -46.28M$ -43.77M$ -36.78M$ -61.50M$ -27.13M$ -24.16M
Basic EPS
$ -3.46$ -3.38$ -3.00$ -11.60--
Diluted EPS
$ -3.46$ -3.38$ -3.00$ -11.60$ -16.20$ -19.60
Basic Average Shares
$ 52.50M$ 12.96M$ 12.16M$ 5.28M$ 1.67M$ 1.24M
Diluted Average Shares
$ 52.50M$ 12.96M$ 12.16M$ 5.28M$ 1.67M$ 1.23M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 3.62M$ 42.02M$ 36.76M$ 60.88M$ 25.58M$ -18.22M
Net Income From Continuing And Discontinued Operation
$ -46.28M$ -43.77M$ -36.78M$ -61.50M$ -27.13M$ -24.16M
Normalized Income
------
Interest Expense
------
EBIT
$ -43.70M$ -41.10M$ -36.73M$ -57.45M$ -25.30M$ -18.01M
EBITDA
$ -41.28M$ -41.09M$ -36.72M$ -57.43M$ -24.21M$ -15.48M
Currency in USD

9 Meters Biopharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis